Speakers

Expand/Collapse

Anil Goyal
Chief Scientific Officer
Immvention Therapeutics

Colin Green
Co-founder & Chief Scientific Officer
OcuNexus Therapeutics

Professor Colin Green is a cell and molecular biologist with 40 years research experience. He holds a Personal Chair in Ophthalmology at the University of Auckland, New Zealand, and has published over 190 full papers and book chapters including two papers in Nature and one in Science. He won the International Robert Feulgen Prize in 1992 for his cardiac gap junction work. He has supervised 57 postgraduate students (27 PhD) to completion and is an applicant on grant funding received at the University of Auckland since 1993 totalling over $23M, including three HRC Programme Grants. In 2004 he co-founded CoDaTherapeutics (NZ) Ltd., and in 2006 CoDa Therapeutics Inc. USA. In 2016 he co-founded OcuNexus Therapeutics, Inc. where he is Chief Scientific Officer. One of his drug candidates is in pivotal final trials for non-healing corneal lesions and one is about to enter Phase II for retinal disease. Colin is an inventor on over 255 patents in 30 patent families and received a Vice-Chancellor’s Commercialisation Medal in 2014.

Day One

Thursday, November 5 2020

10:30 am | Live Q&A

10:00 am | Inhibiting the NLRP3 Inflammasome Activation Signal in Chronic Disease Through Connexin Hemichannel Modulation

Daniel Bachovchin
Assistant Professor
Memorial Sloan Kettering Cancer Center

Dr. Daniel Bachovchin is an Assistant Professor in the Chemical Biology Program at the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center.  His lab is interested in characterizing the roles that proteases play in cancer and immune system signaling. Dr. Bachovchin received his Ph.D. in 2011 from The Scripps Research Institute under the guidance of Dr. Benjamin F. Cravatt.  From 2011-2015, Dr. Bachovchin was a postdoctoral fellow in Dr. Todd Golub’s laboratory at The Broad Institute.

Day Two

Friday, November 6 2020

3:30 pm | Live Q&A Session

2:30 pm | Recent Insights into NLRP1 and CARD8 Inflammasome Activation

Denisa D. Wagner
Professor, Paediatrics
Boston Children’s Hospital

Day Two

Friday, November 6 2020

5:20 pm | Live Q&A Session

4:20 pm | Exploring ASC Speck Formation & NET Formation

Giulio Maria Pasinetti
The Saunders Family Chair and Professor of Neurology
Department of Neurology, Icahn school of Medicine at Mount Sinai

Dr. Giulio Maria Pasinetti is the The Saunders Family Chair and Professor of Neurology, Neuroscience, and Geriatrics and Adult Development at the Ichan School of Medicine at Mount Sinai (ISMMS) in NY. He also serves as the Director of  Basic and Biomedical Research in the Center for Geriatic Research and Training at the Bronx Veterans Affairs Medical Center. He is also the Director of the Center for Molecular Integrative Neuroresilience at the ISMMS. The Center’s goal is to understand the mechanisms of action through which novel therapeutics act against stressful events and to clarify the role of innate immunity in the gut/microbiome-brain axis at the genomic level in the promotion of cognitive and psychological resilience across the lifespan.

Hal Hoffman
Professor of Pediatrics & Medicine
University of California at San Diego & Rady Children's Hospital of San Diego

Hao Wu
Senior Investigator
Harvard Medical School

Iain Kilty
Chief Scientific Officer
Quench Bio

Jenny Ting
Distinguished Professor, Genetics
UNC School of Medicine

Joanne Lim
Senior Scientist, Cellular Immunology
Codiak Biosciences

Day One

Thursday, November 5 2020

4:10 pm | Inhibition of NLRP3 Expression by Exosome Delivery of Antisense Oligonucleotide (ASO)

Johannes Grosse
Senior Director
Vir Biotechnology

Juan Pablo De Rivero Vaccari
Research Assistant Professor
University of Miami Miller School of Medicine

Dr. de Rivero Vaccari is currently a Research Assistant Professor in the Department of Neurological Surgery & The Miami Project to Cure Paralysis. He is also a Distinguished Faculty member of the Center for Cognitive Neuroscience and Aging at the University of Miami Miller School of Medicine. He has studied the innate immune response for 15 years and was the first to show the involvement of the inflammasome complex in vivo in a sterile event, particularly after spinal cord injury.  Dr. de Rivero Vaccari has also contributed to studies of the innate immune response following brain injury, stroke, aging, multiple sclerosis, depression, sciatic nerve pain, Alzheimer’s disease, male infertility, male pattern baldness, wound healing, disc degeneration and corneal degeneration. In addition, he has published biomarker research on stroke, spinal cord and brain traumatic injury, multiple sclerosis, depression and mild cognitive impairment. Dr. de Rivero Vaccari graduated Summa Cum Laude with a B.S. in Biology from Florida International University where he was inducted into The Phi Beta Kappa Honor Society (2004). He then pursued his Ph.D. in Physiology & Biophysics at the University of Miami in the laboratory of Dr. Robert W. Keane (2007) and his post-doctoral fellowship in Neurotrauma at The Miami Project to Cure Paralysis in the laboratory of Dr. W. Dalton Dietrich (2010). In addition, Dr. de Rivero Vaccari has trained on Biomarker Science at the Harvard Clinical and Translational Science Center and on Computational Immunology at the Santa Fe Institute. He is currently pursuing a Master of Science degree in Business Analytics at the Miami Business School of the University of Miami. Dr. de Rivero Vaccari is a co-founder and managing member of InflamaCORE, LLC; an Associate Editor for the Journal Frontiers in Molecular Neuroscience, and a Scientific Advisory Board Member for ZyVersa Therapeutics. He has served as an ad hoc reviewer for over 60 different scientific journals, has co-author over 50 peer-reviewed articles, and his work has been cited over 3,000 times. Dr. de Rivero Vaccari has filed 13 patents in the areas of inflammasome therapeutics and diagnostics.

Day Two

Friday, November 6 2020

3:30 pm | Live Q&A Session

3:00 pm | Targeting Multiple Inflammasomes with IC100, a Monoclonal Antibody Against ASC

Karen Cashmere
Chief Commercial Officer
Zyversa

Kate Fitzgerald
Principal Investigator
Umass Medical School

Dr. Fitzgerald is Professor of Medicine, Director of the Program in Innate Immunity and the Worcester Foundation Chair in Biomedical Sciences at the University of Massachusetts Medical School, Worcester, MA, USA where she has been since 2001. She received her B.Sc. in Biochemistry in 1995 from University College Cork, Ireland and her PhD in Biochemistry in 1999 from Trinity College Dublin, Ireland. Dr. Fitzgerald directs an internationally recognized laboratory focused on understanding the molecular mechanisms controlling the inflammatory response in both health and disease. Her group is interested in determining how the immune system distinguishes friend from foe in order to protect the host from infection and avoid damaging inflammatory responses that lead to a wide range of inflammatory diseases. Her lab uses multifaceted approaches including immunology, biochemistry, molecular biology and genetics to understand the role of inflammasomes, nucleic acid sensing pathways and long non-coding RNAs in the inflammatory response. The long-term goal of her work is to determine how inappropriate activation of innate immunity underlies the pathogenesis of infectious, inflammatory and autoimmune diseases in humans. Dr. Fitzgerald has received several awards including a MERIT award from the NIH, the Saint Patrick’s Day Medal, from the Irish Government and Science Foundation Ireland, the Milstein Award for Excellence in Interferon and Cytokine research (from the International Cytokine and Interferon Society), the Eli Lilly and Company Elanco Research Award (from the American Society of Microbiology) and the BD-Biosciences Investigator Award (from the American Association of Immunologists). She is ranked amongst the top 1% most Cited researchers for Immunology for the last five years (Thompson Reuters, 2014, 2015, 2016, 2017, 2018) and is currently President elect of the International Cytokine and Interferon Society (Fall 2019 term).

Kate Schroder
Director IMB Centre for Inflammation and Disease Research
The University of Queensland

Day Two

Friday, November 6 2020

5:20 pm | Live Q&A Session

4:50 pm | Inflammasome Signalling & Regulation of Cytokines

Lee Simon
Consultant
SDG LLC

Manon Jansen
Senior Clinical Scientist
Centre for Human Drug Research

Marcelo Hill
Chief Scientific Officer
ARDAN Pharma

Marcelo Hill is MD (Universidad de la Republica, Uruguay) and PhD in immunology (Université de Nantes, France). He is the Director of the FOCIS Center of Excellence “Center for Translational Immunology” at Institut Pasteur Montevideo. Dr Hill is Associate Professor of immunology at Universidad de la Republica. He is founder and CSO of ARDAN Immuno Pharma.

Martha O’Brien
Senior Research Scientist
Promega Corporation

Martha O’Brien is a Senior Research Scientist in the Assay Design Group at Promega Corporation and is currently leading assay development efforts focused on inflammasomes and inflammation. Martha received her PhD in biology from the University of North Carolina followed by postdoctoral research in neurobiology at Washington University in St. Louis. She has been a Promega R&D scientist for over two decades and has developed numerous products, is a co-inventor for several patents, and a co-author for several articles.

Day One

Thursday, November 5 2020

9:30 am | Cell-Based Methods to Quantify Inflammasome Activation and Target Engagement

10:30 am | Live Q&A

Matt Devalaraja
Chief Scientific Officer
Corvidia Therapeutics

Meredith Gregory-Ksander
Associate Scientist
Schepens Eye Research Institute, Massachusetts Eye & Ear Hospital

Michael Townsend
Associate Director & Principle Scientist
Genentech

Mike Crackower
Head, Research & Development
Ventus Therapeutics

Dr. Crackower, Head of Research and Development at Ventus Therapeutics, has been leader in drug discovery for over 18 years, with deep expertise in the fields of respiratory, immunology and fibrotic disease drug discovery. Prior to Ventus, Michael was an entrepreneur-in-residence at Versant Ventures where he played an instrumental role in the formation of Ventus. Michael has also held leadership positions at Celgene, Biogen and Merck & Co. Michael holds a PhD in molecular and medical genetics from the University of Toronto.

Pablo Pelegrin
Scientific Deputy Director & Principal Investigator
Biomedical Research Institute of Murcia

Day Two

Friday, November 6 2020

10:00 am | Live Q&A

9:30 am | Exploring the use of Bioluminescent Resonance Energy Transfer to Depict the Mechanism of Action of Novel Inflammasome Inhibitor

Paul Ashton
Chief Executive Officer
Inflammasome Therapeutics

Day One

Thursday, November 5 2020

10:30 am | Live Q&A

9:00 am | Exploring Small Molecule Inflammasome Inhibitors in Retinal Disease

Rebecca Coll
Principal Investigator,
Wellcome-Wolfson Institute for Experimental Medicine
Queen's University Belfast

Dr Rebecca Coll joined the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University Belfast as a Lecturer in Immunobiology in 2019, following her postdoctoral work at the University of Queensland where she studied innate immunity and novel anti-inflammatory molecules. Rebecca received her PhD in Immunology in 2013 in Professor Luke O’Neill’s lab at Trinity College Dublin and moved to Associate Professor Kate Schroder’s group at the Institute for Molecular Bioscience in UQ in 2014. Rebecca's research is focused on inflammasomes – protein complexes at the heart of inflammation and disease – and how these complexes can be targeted therapeutically to prevent damaging inflammation. Rebecca led the biological characterisation of MCC950, a small molecule inhibitor of the NLRP3 inflammasome and an exciting prospect as a new therapy for treating patients with NLRP3-mediated diseases. In 2016 Rebecca was awarded the Research Australia Discovery Award for her work on NLRP3 inhibitors.

Day Two

Friday, November 6 2020

10:00 am | Live Q&A

9:00 am | Determining the Mechanism of Action of Inflammasome Inhibitors

Robert Keane
Professor, Physiology, Biophysics & Neurological Surgery
University of Miami

Day Two

Friday, November 6 2020

3:30 pm | Live Q&A Session

2:00 pm | Ic100: A Novel Anti-Asc Monoclonal Antibody Improves Functional Outcomes in an Animal Model of Multiple Sclerosis

Scott Bowers
Associate Director, Preclinical Pharmacology
Horizon Therapeutics

Day One

Thursday, November 5 2020

5:20 pm | Novel Approach to Identify & Validate Uric Acid-Driven Mediators of Inflammation

5:50 pm | Live Q&A

SY Seong
Chief Executive Officer
Shaperon

Vincent Gruber
Director of New Technology
JEEN International Corporation

Day One

Thursday, November 5 2020

5:50 pm | Live Q&A

4:50 pm | Inflammasomes: Gatekeepers at the front line of skin health

Vishal Singh
Assistant Professor, Nutritional Sciences & Microbiome
Penn State University

William T. Stewart
Chief Executive Officer
TherimuneX

Yiumo Chan
Chief Scientific Officer
Twi Biotechnology